Blue Jet Healthcare IPO

Blue Jet Healthcare Limited

₹14,147 /43 sharesMinimum Investment

Blue Jet Healthcare IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
25 Oct ‘23 - 27 Oct ‘23₹14,14743₹329 - ₹346
Issue SizeIPO Doc
840.27Cr
RHP PDF

Subscription rate

Qualified Institutional Buyers13.72x
Non-Institutional Investor13.59x
Retail Individual Investor2.22x
Employees0.00x
Total7.94x

About Blue Jet Healthcare

Blue Jet Healthcare specializes in pharmaceutical and healthcare ingredients. It focuses on products designed for pharmaceutical companies and generic pharmaceutical companies worldwide. Since its start in 1968, Blue Jet Healthcare has built a contract development and manufacturing organization (CDMO) business model. This model includes expertise in contrast media intermediates and high-intensity sweeteners. Blue Jet Healthcare creates a wide range of products in-house, from starting intermediates to advanced ones. The company's operations are organized into 3 main product categories: contrast media intermediates, high-intensity sweeteners, and pharmaceutical intermediates and active pharmaceutical ingredients (APIs).;
Founded in
1968
Managing director
Mr. Shiven Akshay Arora
Parent organisation
Blue Jet Healthcare Limited

Strengths & Financials of Blue Jet Healthcare

Strengths
Risks
Blue Jet Healthcare contributed to more than 75% of the value of selected contrast media intermediates from India between 2020 and 2022.
In 2020, they introduced a new contrast media intermediate that is the foundation for all gadolinium-based contrast media.
In the past 3 financial years and the 3 months ending June 30, 2023, the company invoiced more than 400 customers in 39 countries.
Blue Jet Healthcare engages in both annual and multi-year supply agreements, ranging from one to four years. More than 70% of their total sales in 2021, 2022, and 2023, as well as the three months ending June 30, 2023, stemmed from contracted sales volumes through annual and multi-year contracts.
Blue Jet Healthcare has fostered partnerships with key clients, including Colgate-Palmolive (India) Limited, Unilever, Prinova US LLC, MMAG Co. Ltd, etc.
Over the past five decades, their R&D center has been instrumental in developing over 100 products, with more than 40 of them reaching commercialization.
With three manufacturing facilities situated in Shahad, Ambernath, and Mahad in Maharashtra, the company has an annual installed capacity of 200.60 KL, 607.30 KL, and 213.00 KL, respectively, as of June 30, 2023.
As customer demand grows, Blue Jet Healthcare's production capacity has expanded, from a combined installed capacity of 230 KL as of March 31, 2018, to 1,020.90 KL as of June 30, 2023.

Blue Jet Healthcare Financials

*All values are in Rs. Cr
No Graph Data To Display

Application Details of Blue Jet Healthcare IPO

Apply asPrice bandApply upto
Regular329 - 346₹2 Lakh
High Networth Individual329 - 346₹2 - 5 Lakh
For Blue Jet Healthcare IPO, eligible investors can apply as Regular.
ⓒ 2016-2024 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 5.6.1
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  GROWWMF |  SBI |  AXIS |  HDFC |  UTI |  NIPPON INDIA |  ICICI PRUDENTIAL |  TATA |  KOTAK |  DSP |  CANARA ROBECO |  SUNDARAM |  MIRAE ASSET |  IDFC |  FRANKLIN TEMPLETON |  PPFAS |  MOTILAL OSWAL |  INVESCO |  EDELWEISS |  ADITYA BIRLA SUN LIFE |  LIC |  HSBC |  NAVI |  QUANTUM |  UNION |  ITI |  MAHINDRA MANULIFE |  360 ONE |  BOI |  TAURUS |  JM FINANCIAL |  PGIM |  SHRIRAM |  BARODA BNP PARIBAS |  QUANT |  WHITEOAK CAPITAL |  TRUST |  SAMCO |  NJ

ABOUT GROWW